Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Our report is an authoritative Owner’s Manual on the company.
- A vital piece in the investor’s toolbox, our report allows you to uncover the essence of the business
- We pinpoint strengths and weaknesses; discuss strategy
- Our aim is to make deep knowledge about the company readily available, saving investors time and enabling dialogue

We offer our research as a service for Japanese corporates.
- Our in-depth reports allow them to better inform investors by presenting an unbiased third-party view of business fundamentals
- Our reports do not offer investment opinions and are free for all investors

We start our coverage with a substantial core report.
- We continuously update this report to reflect earnings, news flow, and any material developments
- We thoroughly interview management on a quarterly basis

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>Revenue increased by 4.2% YoY to JPY7.9bn, but gross profit declined by 21.1% YoY to JPY4.4bn. </li><li>Medical Platform business faced challenges with flat page views and a decline in contract volume by 11.5% YoY. </li><li>Smart Clinic business maintained contract volume with a slight increase in average contract unit price for NOMOCa Stand.</li></ul>

Revenue increased by 4.2% YoY to JPY7.9bn, but gross profit declined by 21.1% YoY to JPY4.4bn. Medical Platform business faced challenges with flat page views and a decline in contract volume by 11.5% YoY. Smart Clinic business maintained contract volume with a slight increase in average contract unit price for NOMOCa Stand.

ジェノバ (9341 JP): 2026年3月期第3四半期速報

GENOVA

ジェノバ (9341 JP): 2026年3月期第3四半期速報